Highlights

  • Adaptimmune Therapeutics (NASDAQ:ADAP) receives an average “Reduce” rating from eight analysts.
  • Two analysts suggest “Sell,” five recommend “Hold,” and one issues a “Buy.”
  • Recent ratings from Guggenheim, HC Wainwright, and Weiss indicate a cautious outlook.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) currently holds an average rating of “Reduce” as reported by MarketBeat Ratings. The review is based on evaluations from eight research firms.

  • Two analysts have assigned a “Sell” recommendation.
  • Five firms recommend “Hold.”
  • One brokerage has issued a “Buy” rating.

The consensus 1-year price target among these analysts stands at USD 1.35.

Recent Analyst Actions

Several research firms have updated their stance on the biotechnology company in recent months.

  • Guggenheim downgraded Adaptimmune from a “Strong Buy” to a “Hold” on July 29.
  • HC Wainwright reaffirmed a “Neutral” rating in its July 29 note.
  • Weiss Ratings issued a “Sell (e+)” recommendation on October 8.

These updates reflect a mixed view on the company’s near-term performance outlook.

Earnings Snapshot

Adaptimmune Therapeutics announced its latest quarterly earnings on August 13. The company reported an earnings per share (EPS) loss of USD 0.11, which was better than the consensus estimate of a USD 0.15 loss.

  • Revenue: USD 13.68 million, exceeding analyst projections of USD 11.04 million.
  • Return on Equity: -163.73%
  • Net Margin: -260.82%

Analysts expect the company to post an EPS of -0.14 for the current year.

Company Overview

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer treatment.

  • Its SPEARHEAD-1 program (ADP-A2M4) is in Phase II for synovial sarcoma.
  • SURPASS-3 targets ovarian cancer patients with platinum resistance.
  • SURPASS is in Phase I trials for head, neck, and urothelial cancers.

The company operates across the United States and the United Kingdom, advancing its T-cell therapy pipeline for oncology applications.